Evidence map›Paper›PMID 42664269›Full record

ArticlePloS one2026

One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases.

Guillaume Bouguéon, Arthur Jouvien, Jean-Marc Bernadou, Arnaud Venet, Aude Berroneau, Pierre Mora, Fabien Xuereb

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guillaume BouguéonUniversity Hospital of Bordeaux, Health Products Department, Hospital Pharmacy Unit, Pessac, France.ORCID https://orcid.org/0000-0003-2447-5310
Arthur JouvienUniversity Hospital of Bordeaux, Health Products Department, Hospital Pharmacy Unit, Pessac, France.
Jean-Marc BernadouUniversity Hospital of Bordeaux, Health Products Department, Hospital Pharmacy Unit, Pessac, France.
Arnaud VenetUniversity Hospital of Bordeaux, Health Products Department, Hospital Pharmacy Unit, Pessac, France.
Aude BerroneauUniversity Hospital of Bordeaux, Health Products Department, Hospital Pharmacy Unit, Pessac, France.ORCID https://orcid.org/0000-0003-3912-7028
Pierre MoraUniversity Hospital of Bordeaux, Health Products Department, Hospital Pharmacy Unit, Pessac, France.ORCID https://orcid.org/0000-0002-0287-0849
Fabien XuerebUniversity Hospital of Bordeaux, Health Products Department, Hospital Pharmacy Unit, Pessac, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idarubicine is a mainstay of the treatment strategy for hematological cancer. The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies. The aim of the present work is to establish the stability of idarubicin preparations diluted in polyolefin-type bags (Freeflex + ®) for intravenous administration in hematological clinical settings. Preparations were produced by diluting Zavedos® idarubicin in Freeflex + ® bags containing 0.9% sodium chloride (NaCl) or 5% dextrose (Dex) at concentrations of 0.04 mg/mL and 0.2 mg/mL. These preparations were stored at 5 ± 3 °C or 22 ± 3 °C. Three bags were prepared to evaluate each condition, for a total of 24 bags. To assess chemical stability, a stability-indicating high pressure liquid chromatography-ultraviolet/visible diode array detector assay was used. Samples were assayed on days D0, D1, D2, D7, D15, D22 and D30. A physical stability study was carried out on days D0, D15 and D30, looking for visible and sub-visible particles, measuring pH and osmolality. During the study, sample concentrations remained above 95% of the initial concentration, and no degradation products were detected. No color change or precipitation were observed with the naked eye. Sub-visible particles count remained below recommended limits. The pH and osmolality values remained unchanged from D0. This study demonstrates the stability of idarubicin, diluted to concentrations between 0.04 and 0.2 mg/mL in solutions of 0.9% NaCl and 5% Dex, stored at 5 ± 3 °C or 22 ± 3 °C for 30 days.

Indexed as

Drug PackagingIdarubicinPolyenesChromatography, High Pressure LiquidDrug StabilityHumansHydrogen-Ion ConcentrationOsmolar ConcentrationIdarubicinPL 732Polyenes

Identifiers

PMID42664269
PMCPMC13524237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.